Fullhope Biomedical Co

Fullhope Biomedical Co EBIT

The EBIT of Fullhope Biomedical Co (7773.TWO) as of Oct 15, 2026 is -64.38 M TWD. In the previous year, EBIT was -43.87 M TWD — a change of 46.75% (lower).

EBIT

-64.38 MTWD

YoY

46.75%

Last updated:

In 2024, Fullhope Biomedical Co's EBIT was -64.38 M TWD, a 46.75% increase from the -43.87 M TWD EBIT recorded in the previous year.

The Fullhope Biomedical Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2022
-44.12 M TWD
Jan 1, 2023
-43.87 M TWD
Jan 1, 2024
-64.38 M TWD
The Fullhope Biomedical Co EBIT history
YEAREBITYoY
-64.38 MTWD+46.75%
-43.87 MTWD-0.58%
-44.12 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fullhope Biomedical Co Revenue

Fullhope Biomedical Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
14.31 M TWD
-44.12 M TWD
-43.75 M TWD
Jan 1, 2023
24.71 M TWD
-43.87 M TWD
-41.74 M TWD
Jan 1, 2024
20.51 M TWD
-64.38 M TWD
-55.91 M TWD

Fullhope Biomedical Co Margins

Fullhope Biomedical Co stock margins

The Fullhope Biomedical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fullhope Biomedical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fullhope Biomedical Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
62.71 %
-308.32 %
-305.76 %
Jan 1, 2023
52.28 %
-177.51 %
-168.90 %
Jan 1, 2024
65.91 %
-313.95 %
-272.65 %

Fullhope Biomedical Co Stock analysis

What does Fullhope Biomedical Co do? Fullhope Biomedical Co Ltd is a Taiwan-based biotechnology company headquartered in Taipei. The company operates in the health care sector with a focus on precision diagnosis and regenerative medicine. Fullhope Biomedical went public on September 26, 2024, with its ticker listed as 7773.TWO. The company's website is https://www.fhb.com.tw/. In the precision diagnosis sector, Fullhope Biomedical has developed an immune function analysis platform and a circulating tumor cell analysis platform. These platforms provide comprehensive information on immune system status and circulating tumor cell data, which can inform follow-up disease treatment strategies. For regenerative medicine, the company maintains a Good Tissue Practice (GTP) laboratory that adheres to regulatory standards. It has established a full-scale manufacturing platform for immune cells and stem cells, producing various cell-based products. The company's operations are based in Taipei, Taiwan, and it is engaged in developing and commercializing products related to precision diagnostics and regenerative medicine. Fullhope Biomedical's business model centers on leveraging advanced biotechnological platforms to support medical treatments and patient care. The company's IPO date marks its entry into the public market, reflecting its growth and development in the biotechnology industry. Fullhope Biomedical's focus on innovative diagnostic and therapeutic solutions positions it within the expanding health care technology sector. Fullhope Biomedical Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Fullhope Biomedical Co's EBIT

Fullhope Biomedical Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Fullhope Biomedical Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Fullhope Biomedical Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Fullhope Biomedical Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Fullhope Biomedical Co stock

EBIT of Fullhope Biomedical Co is -64.38 M TWD in 2024.

EBIT of Fullhope Biomedical Co changed from -43.87 M TWD to -64.38 M TWD, representing a 46.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Fullhope Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Fullhope Biomedical Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Fullhope Biomedical Co

All Key Metrics — Fullhope Biomedical Co